Archive for May 2016
Taking Down The Hospital’s Biggest Killer
By testing white blood cells and monitoring “expression biomarkers,” SeptiCyte – a proprietary technology of Immunexpress – aims to provide faster and more accurate diagnosis of sepsis. By Gregory Zeller.
Read MoreSeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference
SEATTLE, May 18, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III…
Read MoreImmunexpress Announces Presentation at the American Thoracic Society International Conference on the Validation of SeptiCyte™ LAB
SEATTLE, May 11, 2016 — Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial validating SeptiCyte™ Lab as a novel immune response assay to distinguish between SIRS and sepsis in critically ill patients will be presented at the upcoming American Thoracic Society International…
Read MoreAmerican Thoracic Society (ATS) 2016 International Conference
American Thoracic Society 2016 May 13-18, 2016 San Francisco, CA. Bert Lopansri of Intermountain Health Care presented data on the usage of SeptiCyte™ technology to better inform management and reduce risk for patients in the early stages of ICU admission when other diagnostics available at this time either lack accuracy or are not available.
Read More